We published the book "Demystifying Psychiatry" in 2010. Although basic principles of psychiatric treatment remain unchanged, ...

Mental health providers in Central Illinois offering ketamine say it has changed patients' lives for the better. Still, only ...

This week, the US Food and Drug Administration expanded its approval of Spravato, an antidepressant nasal spray. The drug, made by Johnson & Johnson, is now cleared for use as the only standalone ...

The FDA has approved Janssen’s antidepressant ... who have cycled through multiple treatments without relief. Spravato (esketamine) has been touted as a potential blockbuster for Janssen ...

The FDA approval of esketamine (Spravato) in 2019 marked a watershed moment for glutamate-based treatments. As a derivative of ketamine, esketamine acts on NMDA receptors to produce rapid ...

As we honor Counseling Awareness Month,�Relief Mental Health recognizes the critical role that therapy plays in helping individuals navigate mental health challenges and build a life worth living.

The U.S. FDA approved Spravato (esketamine) in 2019 for fast alleviation of depression symptoms. But it requires close medical supervision because of potential dissociative effects, risks of ...

The FDA has cleared Auvelity (dextromethorphan ... That status goes to Johnson & Johnson's Spravato (esketamine), which was approved in March 2019 and is administered as a nasal spray twice ...

Johnson & Johnson’s Q1 2025 earnings reveal growth in sales and EPS, boosted by MedTech and Pharma. Click for my updated look at JNJ and its most recent news.

The expansion is effective immediately, nearly one year after NeuroStar ® Advanced Therapy received FDA clearance as the first first-line ... Greenbrook treatment centers also offer SPRAVATO ® ...

Doug Drysdale, CEO of Cybin opens up to Invezz about the benefits of psychedelics based drugs, why psychedelic stocks are struggling and how Big Pharma may soon get involved in the sector.